An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Gedatolisib|DRUG: PTK7-ADC
Sponsor: Kathy Miller